Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Idea Of The Day -- Ignore unavailable to you. Want to Upgrade?

To: IQBAL LATIF who wrote (30458)	1/14/2000 5:08:00 AM
From: IQBAL LATIF	Respond to of 50167

Breakthrough Cancer News for ISIS Pharmaceuticals Reed Williams, MD Isis Pharmaceuticals NASDAQ:ISIP Health Care Quote \| News \| Snapshot \| Charts \| SEC \| Ratings Jan 13 2000 It looks like a self-fulfilling prophecy. In an article posted here only last week, ISIS Pharmaceuticals ? Down but Not Out, we mentioned that good things were on the horizon for ISIS Pharmaceuticals (ISIP). To many observers, it looked like ISIP was down for the count after December?s crushing blow delivered by halting clinical trials on their promising Crohn?s disease medication. In suitable fashion, the company?s stock was pummeled, losing nearly 70% of its value overnight. How quickly things turn on the announcement of good news. Late in the day yesterday, ISIP announced positive research findings for their antisense drug, ISIS 5132, in the treatment of cancer patients. The finding was released in an article in the latest issue of Clinical Cancer Research. Basically, antisense drugs are designed to block messenger ribonucleic acid (mRNA), one of the basic building blocks for cellular construction. ISIS 5132 was given to 14 patients with advanced cancer. 13 of the 14 patients indicated a dramatic reduction of c-raf-1 mRNA levels, a type of mRNA felt to play a key role in cancer. While there has been speculation that antisense drugs might not work as hoped, this paper showed a good response. Does this promise a cure for cancer? Far from it. This is a significant step in our understanding of cancer, and gives us a potentially important weapon against the disease. Much research must be done to prove out the initial findings, and ensure that there are not any serious adverse side effects. On the news yesterday, the share prices jumped 36% higher in late trading and after hours. This should not be the last of the good news to come out of ISIP?s research pipeline. While we are expecting a restructuring of the company to be announced almost any day, we anticipate more positive events for the company in the months ahead

To: IQBAL LATIF who wrote (30458)	1/14/2000 9:04:00 AM
From: N	Respond to of 50167

Ike, core CPI up 0.1% ... lower than expected biz.yahoo.com "...Consumer Price Index (CPI) rose 0.2 percent while CPI excluding food and energy advanced 0.1 percent in December. In November, overall CPI rose by 0.1 percent while core CPI increased 0.2 percent. Economists surveyed by Reuters predicted, on average, that overall CPI would gain 0.3 percent while the core reading would gain 0.2 percent in December. CAROL STONE, SENIOR ECONOMIST, NOMURA SECURITIES INTERNATIONAL, NY: ''It's a very good number and the lowest core rate in 34 years.'' ..." Nancy